Sawh Sonja C, Deshpande Santosh, Jansen Sandy, Reynaert Christopher J, Jones Philip M
Department of Pharmacy, London Health Sciences Centre, London, Ontario, Canada.
Departments of Anesthesia & Perioperative Medicine and Epidemiology & Biostatistics, University of Western Ontario, London, Ontario, Canada.
PeerJ. 2016 Oct 5;4:e2429. doi: 10.7717/peerj.2429. eCollection 2016.
Necrotizing enterocolitis (NEC) is the most frequent gastrointestinal emergency in neonates. The microbiome of the preterm gut may regulate the integrity of the intestinal mucosa. Probiotics may positively contribute to mucosal integrity, potentially reducing the risk of NEC in neonates.
To perform an updated systematic review and meta-analysis on the efficacy and safety of probiotics for the prevention of NEC in premature infants.
Structured searches were performed in: Medline, Embase, and the Cochrane Central Register of Controlled Trials (all via Ovid, from 2013 to January 2015). Clinical trial registries and electronically available conference materials were also searched. An updated search was conducted June 3, 2016.
Randomized trials including infants less than 37 weeks gestational age or less than 2,500 g on probiotic vs. standard therapy.
Data extraction of the newly-identified trials with a double check of the previously-identified trials was performed using a standardized data collection tool.
Thirteen additional trials ( = 5,033) were found. The incidence of severe NEC (RR 0.53 95% CI [0.42-0.66]) and all-cause mortality (RR 0.79 95% CI [0.68-0.93]) were reduced. No difference was shown in culture-proven sepsis RR 0.88 95% CI [0.77-1.00].
Heterogeneity of organisms and dosing regimens studied prevent a species-specific treatment recommendation from being made.
Preterm infants benefit from probiotics to prevent severe NEC and death.
坏死性小肠结肠炎(NEC)是新生儿中最常见的胃肠道急症。早产肠道的微生物群可能调节肠黏膜的完整性。益生菌可能对黏膜完整性有积极作用,有可能降低新生儿患NEC的风险。
对益生菌预防早产儿NEC的疗效和安全性进行最新的系统评价和荟萃分析。
在以下数据库进行结构化检索:医学期刊数据库(Medline)、荷兰医学文摘数据库(Embase)和Cochrane对照试验中心注册库(均通过Ovid检索,检索时间为2013年至2015年1月)。还检索了临床试验注册库和电子可得的会议资料。2016年6月3日进行了更新检索。
随机试验,纳入孕周小于37周或出生体重小于2500g的婴儿,比较益生菌与标准治疗。
使用标准化数据收集工具对新识别的试验进行数据提取,并对先前识别的试验进行二次核对。
又发现了13项试验(n = 5033)。严重NEC的发生率(RR 0.53,95%CI[0.42 - 0.66])和全因死亡率(RR 0.79,95%CI[0.68 - 0.93])降低。经培养证实的败血症方面未显示差异(RR 0.88,95%CI[0.77 - 1.00])。
所研究的微生物和给药方案的异质性使得无法给出特定物种的治疗建议。
早产儿受益于益生菌预防严重NEC和死亡。